The unveiling ceremony took place in Tehran on Wednesday, with Mohamad Eslami, head of Iran’s atomic energy organization.
Concentrated dioxide powder containing the stable isotope Tellurium-130 is a necessary ingredient for the production of iodine-131, a radiopharmaceutical commonly used in imaging, hyperthyroidism treatment, and thyroid cancer treatment.
Iodine-131 radiopharmaceuticals are produced through complex processes in the Tehran research reactor.
With the achievement of a complete production cycle of this radiopharmaceutical raw materials, Iran is currently establishing a stable and complete domestic production capacity of iodine-131.
By manufacturing this product domestically, in addition to meeting domestic needs and saving foreign currency, Iran has gained the potential to enter the international market.
Self-sufficiency in the production of strategic products, particularly radiopharmaceuticals, is considered a principle of passive defense.
MP/FNA1740568775461791589